Ardelyx(US:ARDX) The Motley Fool·2026-03-01 22:58Company Overview - Ardelyx is a biotech company focused on innovative therapies for gastrointestinal conditions and chronic kidney disease, with a strong client base in the U.S. and partnerships in Canada, China, and Japan [6]. Financial Performance - For the fiscal year 2025, Ardelyx reported Q4 earnings showing four consecutive years of revenue growth and a declining net loss, with total revenue of approximately $407.32 million and a net loss of $61.60 million [5][7]. - The company's stock price increased approximately 18% in 2025 and is currently up 15% in 2026 [9]. Recent Transactions - On February 24, 2026, Ardelyx President and CEO Michael Raab sold 41,666 shares of Common Stock for approximately $261,000, retaining 1,836,153 shares directly and 25,364 shares indirectly post-transaction [1][2][4]. Strategic Partnerships - On February 24, 2026, Ardelyx announced a multi-year partnership with the Ladies Professional Golf Association (LPGA) to educate and mobilize women in health, focusing on digestive health issues such as irritable bowel syndrome and constipation [8]. Market Activity - The current market capitalization of Ardelyx is approximately $1.6 billion, with a current stock price of $6.54 and a day's trading range between $6.34 and $6.61 [4][5]. - There is speculation regarding a potential acquisition of Ardelyx, with rumors suggesting that Indian pharmaceutical company Zydus Lifesciences is exploring a majority stake in Ardelyx [9].